Sign In
Buy NUVL
$90.18
-1.17 (-1.28%)
At Close: Jun 03, 2026
Commercial preparations well underway to support potential U.S. launch of zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC population, pending FDA review; PDUFA target action date of Septe
Biotech Fund Dumps $84 Million of Nuvalent With Stock Up 29%
10:01am, Monday, 23'rd Feb 2026
Commodore Capital reduced its Nuvalent stake by 850,000 shares in the fourth quarter; the estimated trade size was $83.81 million based on quarterly average pricing. Meanwhile, the quarter-end positio
Nuvalent Details FDA Timelines for ROS1, ALK Drugs as $1.4B Cash Fuels Global Launch Plans
01:02am, Monday, 16'th Feb 2026
Nuvalent (NASDAQ: NUVL) executives highlighted ongoing regulatory milestones for the company's lead oncology programs and discussed commercialization strategy, pipeline plans, and financial positionin
Nuvalent to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
06:30am, Thursday, 05'th Feb 2026
CAMBRIDGE, Mass., Feb. 5, 2026 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase t
Nuvalent, Inc. (NASDAQ:NUVL) Given Consensus Recommendation of “Moderate Buy” by Brokerages
02:23am, Monday, 26'th Jan 2026
Shares of Nuvalent, Inc. (NASDAQ: NUVL - Get Free Report) have earned an average rating of "Moderate Buy" from the sixteen research firms that are currently covering the company, Marketbeat reports. O
3 Biotech Stocks That Could Double In 2026
10:42am, Tuesday, 20'th Jan 2026
The biotech sector is one that's become red-hot, at least in recent years. After around a decade of stagnation, investors appear to be intent on increasing their exposure to top biotech names in the m
Nuvalent, Inc. (NUVL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
03:26pm, Tuesday, 13'th Jan 2026
Nuvalent, Inc. (NUVL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Nuvalent Announces OnTarget 2026 Operating Plan Progress and Outlines Key Anticipated 2026 Milestones
06:30am, Monday, 12'th Jan 2026
FDA accepted NDA for zidesamtinib for the treatment of TKI pre-treated patients with advanced ROS1-positive NSCLC; PDUFA target action date of September 18, 2026 NDA submission for neladalkib in TKI
Nuvalent (NASDAQ:NUVL) CFO Sells $412,247.52 in Stock
06:26am, Saturday, 10'th Jan 2026
Nuvalent, Inc. (NASDAQ: NUVL - Get Free Report) CFO Alexandra Balcom sold 4,236 shares of Nuvalent stock in a transaction on Monday, January 5th. The shares were sold at an average price of $97.32, fo
Nuvalent (NASDAQ:NUVL) Insider Sells $412,247.52 in Stock
06:26am, Saturday, 10'th Jan 2026
Nuvalent, Inc. (NASDAQ: NUVL - Get Free Report) insider Christopher Durant Turner sold 4,236 shares of the stock in a transaction that occurred on Monday, January 5th. The shares were sold at an avera
Nuvalent (NASDAQ:NUVL) Insider Sells $424,607.16 in Stock
06:26am, Saturday, 10'th Jan 2026
Nuvalent, Inc. (NASDAQ: NUVL - Get Free Report) insider Deborah Ann Miller sold 4,363 shares of Nuvalent stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $97
James Richard Porter Sells 17,890 Shares of Nuvalent (NASDAQ:NUVL) Stock
04:33am, Friday, 09'th Jan 2026
Nuvalent, Inc. (NASDAQ: NUVL - Get Free Report) CEO James Richard Porter sold 17,890 shares of Nuvalent stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $9
What's Going On With Royalty Pharma Stock Wednesday?
10:47am, Wednesday, 31'st Dec 2025
Royalty Pharma has acquired PTC's remaining royalty on Roche's Evrysdi for $240 million upfront and sales-based milestones.
3 Biotech Stocks With Major 2026 Catalysts
10:15am, Monday, 29'th Dec 2025
Biotech's 2025 rebound sets the stage for Denali Therapeutics and two peers, with key FDA decisions and pipeline catalysts lined up for 2026.
Nuvalent to Present at the 44th Annual J.P. Morgan Healthcare Conference
06:30am, Monday, 22'nd Dec 2025
CAMBRIDGE, Mass. , Dec. 22, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven ki
